Kymera Therapeutics(US:KYMR) Globenewswire·2025-09-17 11:00Core Insights - Kymera Therapeutics announced positive Phase 1 trial results for KT-621, an oral STAT6 degrader, which will be presented at major European congresses [1][2] - KT-621 shows potential to provide a novel oral therapy for immuno-inflammatory diseases like atopic dermatitis and asthma, with data expected from ongoing trials in late 2025 [2][4] - The drug demonstrated over 90% mean STAT6 degradation in blood and skin, with significant reductions in Th2 biomarkers, indicating its effectiveness compared to dupilumab [2][3] Group 1: Clinical Trial Results - KT-621 achieved over 90% mean STAT6 degradation at doses above 1.5 mg, with complete degradation at doses ≥50 mg [2] - The drug showed median TARC reduction of up to 37% and median Eotaxin-3 reduction of up to 63%, indicating a strong impact on disease-relevant biomarkers [2] - The ongoing BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is expected to report data in Q4 2025 [4] Group 2: Future Development Plans - Two Phase 2b trials for KT-621 in atopic dermatitis and asthma are set to begin in Q4 2025 and Q1 2026, respectively [4] - The Phase 2b studies aim to accelerate the development of KT-621 for subsequent Phase 3 registration studies across multiple indications [4] - The company is focused on advancing its pipeline of oral small molecule degraders to provide effective therapies for Th2 diseases affecting over 130 million patients globally [7] Group 3: Presentation Details - KT-621 will be featured in late-breaking oral presentations at the EADV Congress on September 17, 2025, and the ERS Congress on September 29, 2025 [5][6] - The presentations will cover safety, pharmacokinetics, pharmacodynamics, and the drug's effects on Th2 biomarkers [5][6] - Copies of the presentations will be available on Kymera's website following the sessions [6]